HRP990246A2
(en)
|
1998-08-07 |
2000-06-30 |
Du Pont Pharm Co |
Succinoylamino benzodiazepines as inhibitors of a beta protein production
|
WO2000038618A2
(fr)
|
1998-12-24 |
2000-07-06 |
Du Pont Pharmaceuticals Company |
BENZODIAZEPINES SUCCINOYLAMINO UTILISEES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A$g(b)
|
US6503902B2
(en)
|
1999-09-13 |
2003-01-07 |
Bristol-Myers Squibb Pharma Company |
Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
|
US6960576B2
(en)
|
1999-09-13 |
2005-11-01 |
Bristol-Myers Squibb Pharma Company |
Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
|
AU7997700A
(en)
|
1999-10-08 |
2001-04-23 |
Du Pont Pharmaceuticals Company |
Amino lactam sulfonamides as inhibitors of abeta protein production
|
EP1232147B1
(fr)
|
1999-11-15 |
2008-04-02 |
Janssen Pharmaceutica N.V. |
Triazoles utilises comme inhibiteurs de farnesyl transferase
|
US7049324B1
(en)
|
1999-11-15 |
2006-05-23 |
Ashis Kumar Saha |
Triazoles as farnesyl transferase inhibitors
|
WO2001060826A2
(fr)
|
2000-02-17 |
2001-08-23 |
Bristol-Myers Squibb Pharma Company |
CARBOCYCLES ET HETEROCYCLES SUCCINOYLAMINO UTILISES EN TANT QU'INHIBITEURS DE LA PRODUCTION DE LA PROTEINE A$g(b)
|
WO2001074783A1
(fr)
|
2000-04-03 |
2001-10-11 |
Dupont Pharmaceuticals Company |
Lactames cycliques utilises comme inhibiteurs de la production de la proteine beta-amyloide
|
AU2001253108A1
(en)
|
2000-04-03 |
2001-10-15 |
Bristol-Myers Squibb Pharma Company |
Cyclic lactams as inhibitors of a-beta protein production
|
WO2001077086A1
(fr)
|
2000-04-11 |
2001-10-18 |
Dupont Pharmaceuticals Company |
LACTAMES SUBSTITUES UTILISES EN TANT QU'INHIBITEURS DE PRODUCTION DE PROTEINE A$g(b)
|
MXPA02000862A
(es)
|
2000-06-01 |
2003-07-14 |
Bristol Myers Squibb Pharma Co |
Lactamas substituidas por succinatos ciclicos como inhibidores de la produccion de proteina abeta.
|
EP1301483A1
(fr)
*
|
2000-07-18 |
2003-04-16 |
Basf Aktiengesellschaft |
1-aryl-4-halogenure d'alkyl-2-(1h)-pyridones et leur utilisation en tant qu'herbicides
|
US7053088B2
(en)
|
2002-05-22 |
2006-05-30 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
KR20050055694A
(ko)
|
2002-08-08 |
2005-06-13 |
암젠 인코포레이티드 |
바닐로이드 수용체 리간드 및 치료시 이들의 용도
|
MY139645A
(en)
|
2004-02-11 |
2009-10-30 |
Amgen Inc |
Vanilloid receptor ligands and their use in treatments
|
WO2005077938A1
(fr)
|
2004-02-11 |
2005-08-25 |
Amgen Inc. |
Ligands du recepteur vanilloide et leurs applications dans des traitements
|
AP2007004047A0
(en)
|
2005-01-20 |
2007-06-30 |
Pfizer Ltd |
Substituted triazole derivatives as oxtocin antagonists
|
US7301022B2
(en)
|
2005-02-15 |
2007-11-27 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
SI2404919T1
(sl)
|
2005-11-08 |
2013-12-31 |
Vertex Pharmaceuticals Incorporated |
Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2008039327A2
(fr)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
US7754739B2
(en)
|
2007-05-09 |
2010-07-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
PL2336120T3
(pl)
|
2007-01-10 |
2014-12-31 |
Msd Italia Srl |
Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
CA2686838C
(fr)
|
2007-05-09 |
2017-03-14 |
Vertex Pharmaceuticals Incorporated |
Modulateurs de cftr
|
CA2685967A1
(fr)
|
2007-05-21 |
2008-11-21 |
Novartis Ag |
Inhibiteurs de cfs-1r, compositions et methodes d'utilisation connexes
|
CA2690191C
(fr)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
Derives de 4-carboxybenzylamino utilises en tant qu'inhibiteurs de l'histone desacetylase
|
PT2639222T
(pt)
|
2007-12-07 |
2016-11-01 |
Vertex Pharma |
Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicos
|
CA2706920C
(fr)
|
2007-12-07 |
2018-02-13 |
Vertex Pharmaceuticals Incorporated |
Formes solides d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoique
|
ES2647531T3
(es)
|
2008-02-28 |
2017-12-22 |
Vertex Pharmaceuticals Incorporated |
Derivados de heteroarilo como moduladores de CFTR
|
WO2010114780A1
(fr)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de l'activité akt
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
PE20121172A1
(es)
|
2009-10-14 |
2012-09-05 |
Merck Sharp & Dohme |
Piperidinas sustituidas con actividad en la hdm2
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
BR112012023021A2
(pt)
|
2010-03-16 |
2016-05-31 |
Dana Farber Cancer Inst Inc |
compostos de indazol e seus usos
|
HRP20211752T1
(hr)
|
2010-04-07 |
2022-02-18 |
Vertex Pharmaceuticals Incorporated |
Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
CA2805265A1
(fr)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Inhibition a mediation par interference arn de catenine (proteine associee a cadherine), expression du gene beta 1 (ctnnb1) a l'aide de petit acide nucleique interferent (sian)
|
CA2807307C
(fr)
|
2010-08-17 |
2021-02-09 |
Merck Sharp & Dohme Corp. |
Inhibition mediee par des arn interferents de l'expression genique du virus de l'hepatite b (vhb) a l'aide de petits acides nucleiques interferents (pani)
|
EP2608669B1
(fr)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP2632472B1
(fr)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Inhibition facilitée par l'interférence d'arn de l'expression d'un gène au moyen d'acides nucléiques interférents courts (sina)
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
IN2013MN02170A
(fr)
|
2011-04-21 |
2015-06-12 |
Piramal Entpr Ltd |
|
WO2013063214A1
(fr)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Nouveaux composés qui sont des inhibiteurs d'erk
|
EP3569598A1
(fr)
|
2011-11-17 |
2019-11-20 |
Dana Farber Cancer Institute, Inc. |
Inhibiteurs de la kinase c-jun-n-terminale (jnk)
|
EP2844261B1
(fr)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
Compositions de petit acide nucléique interférent (sina)
|
WO2014052563A2
(fr)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Nouveaux composés inhibiteurs de erk
|
EP2909194A1
(fr)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
|
WO2014063061A1
(fr)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
|
WO2014063054A1
(fr)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
|
MX363243B
(es)
|
2012-11-28 |
2019-03-14 |
Merck Sharp & Dohme |
Composiciones para tratar cáncer y usos de dichas composiciones.
|
BR112015013611A2
(pt)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
composto, e, composição farmacêutica
|
EP2951180B1
(fr)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
|
EP3041938A1
(fr)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Polynucléotides circulaires
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
ES2676734T3
(es)
|
2013-10-18 |
2018-07-24 |
Syros Pharmaceuticals, Inc. |
Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
|
PL3068392T3
(pl)
|
2013-11-12 |
2021-07-19 |
Vertex Pharmaceuticals Incorporated |
Proces wytwarzania kompozycji farmaceutycznych do leczenia chorób, w których pośredniczy cftr
|
WO2015164604A1
(fr)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
SG10201900631TA
(en)
|
2014-08-01 |
2019-02-27 |
Nuevolution As |
Compounds active towards bromodomains
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
JP6494757B2
(ja)
|
2014-11-18 |
2019-04-03 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
ハイスループット試験高速液体クロマトグラフィーを行うプロセス
|
JP6854762B2
(ja)
|
2014-12-23 |
2021-04-07 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼ7(cdk7)の阻害剤
|
JP6861166B2
(ja)
|
2015-03-27 |
2021-04-21 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
CA2996978A1
(fr)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de kinases cycline-dependantes
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
MX2019012233A
(es)
|
2017-04-13 |
2020-01-14 |
Aduro Biotech Holdings Europe Bv |
Anticuerpos anti-sirpa.
|
WO2019094311A1
(fr)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de prmt5
|
WO2019148412A1
(fr)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anticorps bispécifiques anti-pd-1/lag3
|
US20210277009A1
(en)
|
2018-08-07 |
2021-09-09 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033284A1
(fr)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de prmt5
|
CN111848521A
(zh)
*
|
2020-08-26 |
2020-10-30 |
韶远科技(上海)有限公司 |
一种2-取代-4-烷氧基咪唑化合物的制备方法
|